Does the media prefer BBIO or DYN?

In the previous week, Dyne Therapeutics had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.49 beat Dyne Therapeutics' score of 0.36 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DYN or RDY?

Dyne Therapeutics currently has a consensus target price of $34.17, indicating a potential upside of 40.78%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer DYN or RDY?

In the previous week, Dyne Therapeutics had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Dyne Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.38 beat Dyne Therapeutics' score of 0.36 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DYN or AXSM?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Dyne Therapeutics. Axsome Therapeutics' average media sentiment score of 1.04 beat Dyne Therapeutics' score of 0.36 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or DYN?

In the previous week, Dyne Therapeutics had 5 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Dyne Therapeutics' score of 0.36 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARWR or DYN?

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 9 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.24 beat Dyne Therapeutics' score of 0.36 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyne Therapeutics (DYN) Competitors

$24.27 +0.44 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$24.28 +0.00 (+0.02%)

As of 05:55 PM Eastern

Compare

DYN vs. BBIO, RDY, AXSM, ELAN, and ARWR

Should you buy Dyne Therapeutics stock or one of its competitors? MarketBeat compares Dyne Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyne Therapeutics include BridgeBio Pharma (BBIO), Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Dyne Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Dyne Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	35.18	-$724.93M	-$3.74	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

In the previous week, Dyne Therapeutics had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.49 beat Dyne Therapeutics' score of 0.36 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Dyne Therapeutics	N/A	-58.28%	-46.77%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

BridgeBio Pharma presently has a consensus target price of $92.90, suggesting a potential upside of 3.03%. Dyne Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 40.78%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Dyne Therapeutics beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Dyne Therapeutics (NASDAQ:DYN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

In the previous week, Dyne Therapeutics had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Dyne Therapeutics and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.38 beat Dyne Therapeutics' score of 0.36 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Dyne Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Dyne Therapeutics currently has a consensus target price of $34.17, indicating a potential upside of 40.78%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Dr. Reddy's Laboratories	$3.58B	3.24	$456M	$0.58	23.94

Dyne Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

Dyne Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Axsome Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dyne Therapeutics presently has a consensus target price of $34.17, suggesting a potential upside of 40.78%. Axsome Therapeutics has a consensus target price of $259.05, suggesting a potential upside of 4.06%. Given Dyne Therapeutics' higher probable upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Axsome Therapeutics has higher revenue and earnings than Dyne Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Axsome Therapeutics	$638.50M	20.06	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Dyne Therapeutics. Axsome Therapeutics' average media sentiment score of 1.04 beat Dyne Therapeutics' score of 0.36 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Dyne Therapeutics' return on equity of -58.28% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Dyne Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Summary

Dyne Therapeutics and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Elanco Animal Health has higher revenue and earnings than Dyne Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.61	-$232M	-$0.50	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

In the previous week, Dyne Therapeutics had 5 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Dyne Therapeutics and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Dyne Therapeutics' score of 0.36 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Elanco Animal Health presently has a consensus price target of $28.55, suggesting a potential upside of 15.88%. Dyne Therapeutics has a consensus price target of $34.17, suggesting a potential upside of 40.78%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Elanco Animal Health beats Dyne Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Arrowhead Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $87.27, suggesting a potential upside of 3.91%. Dyne Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 40.78%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 9 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.24 beat Dyne Therapeutics' score of 0.36 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.26	-$1.63M	-$2.15	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Summary

Dyne Therapeutics beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.94B	$3.10B	$6.93B	$12.49B
Dividend Yield	N/A	2.08%	2.68%	7.79%
P/E Ratio	-7.54	19.93	27.39	24.62
Price / Sales	N/A	493.82	549.66	113.75
Price / Cash	N/A	57.49	48.45	59.17
Price / Book	3.56	4.38	11.02	6.46
Net Income	-$446.21M	$64.32M	$3.57B	$331.60M
7 Day Performance	5.20%	0.24%	0.41%	-0.42%
1 Month Performance	35.44%	7.28%	5.76%	2.09%
1 Year Performance	173.31%	25.39%	31.25%	22.24%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	2.9023 of 5 stars	$24.27 +1.8%	$34.17 +40.8%	+184.0%	$3.94B	N/A	N/A	100	Analyst Upgrade Insider Trade
BBIO BridgeBio Pharma	1.7261 of 5 stars	$72.01 +2.5%	$92.90 +29.0%	+81.4%	$13.76B	$502.08M	N/A	400	News Coverage Options Volume Gap Up
RDY Dr. Reddy's Laboratories	1.8468 of 5 stars	$14.88 -3.3%	N/A	-4.2%	$12.84B	$3.58B	25.65	27,527	News Coverage Gap Down High Trading Volume
AXSM Axsome Therapeutics	2.2837 of 5 stars	$241.12 -0.2%	$258.95 +7.4%	+126.5%	$12.44B	$638.50M	N/A	380	News Coverage Positive News Analyst Forecast
ELAN Elanco Animal Health	3.7478 of 5 stars	$24.76 +0.8%	$28.55 +15.3%	+67.4%	$12.27B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. BBIO, RDY, AXSM, ELAN, and ARWR

How does Dyne Therapeutics compare to BridgeBio Pharma?

Summary

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. BBIO, RDY, AXSM, ELAN, and ARWR

How does Dyne Therapeutics compare to BridgeBio Pharma?

Which has stronger valuation and earnings, BBIO or DYN?

Does the media prefer BBIO or DYN?

Is BBIO or DYN more profitable?

Do insiders & institutionals hold more shares of BBIO or DYN?

Which has more volatility & risk, BBIO or DYN?

Do analysts recommend BBIO or DYN?

Summary

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Does the media prefer DYN or RDY?

Is DYN or RDY more profitable?

Do analysts rate DYN or RDY?

Do insiders & institutionals believe in DYN or RDY?

Which has stronger valuation and earnings, DYN or RDY?

Which has more risk & volatility, DYN or RDY?

Summary

How does Dyne Therapeutics compare to Axsome Therapeutics?

Do insiders and institutionals believe in DYN or AXSM?

Do analysts rate DYN or AXSM?

Which has stronger valuation and earnings, DYN or AXSM?

Does the media refer more to DYN or AXSM?

Is DYN or AXSM more profitable?

Which has more risk and volatility, DYN or AXSM?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Which has preferable earnings & valuation, ELAN or DYN?

Does the media prefer ELAN or DYN?

Is ELAN or DYN more profitable?

Do analysts rate ELAN or DYN?

Do insiders & institutionals hold more shares of ELAN or DYN?

Which has more volatility and risk, ELAN or DYN?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more volatility & risk, ARWR or DYN?

Do analysts rate ARWR or DYN?

Do insiders and institutionals hold more shares of ARWR or DYN?

Does the media favor ARWR or DYN?

Is ARWR or DYN more profitable?

Which has stronger valuation & earnings, ARWR or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools